Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Shares Outstanding (2016 - 2025)

United Therapeutics (UTHR) has disclosed Shares Outstanding for 17 consecutive years, with $76.5 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 1.94% to $76.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $76.5 million through Dec 2025, up 1.94% year-over-year, with the annual reading at $76.5 million for FY2025, 1.94% up from the prior year.
  • Shares Outstanding hit $76.5 million in Q4 2025 for United Therapeutics, up from $42.9 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $76.5 million in Q4 2025 to a low of $42.9 million in Q3 2025.
  • Historically, Shares Outstanding has averaged $70.4 million across 5 years, with a median of $73.0 million in 2022.
  • Biggest five-year swings in Shares Outstanding: rose 1.95% in 2023 and later crashed 42.64% in 2025.
  • Year by year, Shares Outstanding stood at $71.7 million in 2021, then increased by 1.39% to $72.7 million in 2022, then rose by 1.38% to $73.7 million in 2023, then increased by 1.76% to $75.0 million in 2024, then increased by 1.94% to $76.5 million in 2025.
  • Business Quant data shows Shares Outstanding for UTHR at $76.5 million in Q4 2025, $42.9 million in Q3 2025, and $75.4 million in Q2 2025.